Prevention of recurrent life-threatening arrhythmias: Will lipid-lowering therapy make a difference?

Journal of the American College of Cardiology

Volumn 36, Issue 3, 2000, Pages 773-775

  Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

CLINICAL TRIAL; DEFIBRILLATOR; DRUG ACTIVITY; EDITORIAL; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION;

ANTILIPEMIC AGENTS; ARRHYTHMIA; CORONARY DISEASE; CRITICAL ILLNESS; HUMANS; RECURRENCE;

EID: 0033860630     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00806-8     Document Type: Editorial

References (28)

1. Current perspectives on statins
2. The evolving role of statins in the management of atherosclerosis
3. Randomised trial for cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
8. Sudden cardiac death
9. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
10. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
11. Restoration of endothelial-dependent relaxation by dietary treatment of atherosclerosis
12. Cholesterol lowering and coronary artery disease: Mechanism of risk reduction
13. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production
14. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
15. Inhibition of the mevalonate pathway: Benefits beyond the cholesterol pathway?
16. Reduction of serum cholesterol levels alters lesional composition of atherosclerosis in mature WHHL rabbits
17. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
18. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
19. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients
20. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
21. A randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)
22. A randomized trial of the implantable cardioverter defibrillator against amiodarone
23. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: Significance of combining beta-blockers with amiodarone
24. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial
25. Anatomic features in victims of sudden coronary death: Coronary artery pathology
26. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate
27. Incidence of implantable defibrillator discharges after coronary revascularization in survivors of ischemic sudden cardiac death
28. Coronary artery bypass grafting and defibrillator implantation in patients with ventricular tachyarrhythmias and ischemic heart disease